German pharmaceutical group STADA has approved a €20 million investment to expand production at Hemofarm’s manufacturing complex, strengthening the Serbian facility’s position within the group’s international production network.
STADA CEO said the group’s global executive board approved the investment. The project will expand production and add manufacturing capacity at the Vršac site. Hemofarm already supplies pharmaceutical products from Vršac to markets across the European Union, the Middle East and other international destinations. Germany is the company’s largest export market.
Hemofarm’s role in STADA’s production network
Hemofarm employs approximately 4,500 people, making it one of Serbia’s largest pharmaceutical manufacturers and a major industrial employer outside Belgrade. STADA has invested approximately €537 million in Hemofarm and its regional development over the past 20 years.
The new investment will add capacity to an established manufacturing operation rather than create a new greenfield facility. The Vršac complex already has qualified personnel, regulatory systems and established access to international supply chains. The expansion will therefore increase production capacity at an existing Serbian pharmaceutical manufacturing base within STADA’s broader European network.
Investment in regulated pharmaceutical manufacturing
Pharmaceutical manufacturing operates under strict quality-control requirements, validated production processes and regulatory standards governing access to international markets. The additional capacity at Vršac will further expand Hemofarm’s manufacturing operations in a sector that serves both domestic and export markets. The company’s existing international distribution footprint means production from Serbia is already connected to demand outside the country, including the European Union and Germany as its largest export destination.
Potential effects across the supply chain
The expansion will also increase the scale of activity surrounding Hemofarm’s manufacturing operations. A larger pharmaceutical production base can generate additional requirements for services and suppliers connected with packaging, logistics, laboratory activities and specialised industrial maintenance. The Vršac facility’s existing export operations and STADA’s latest capacity investment place the Serbian plant within the group’s wider allocation of pharmaceutical production across its international network.
